ABSTRACT
This longitudinal single-center study describes the timing and risk factors for genital human papillomavirus (HPV) disease in women after allogeneic hematopoietic cell transplantation (HCT). Between 1994 and 2014, 109 females underwent HCT of whom 82 surviving transplant for >1 year had regular, comprehensive genital tract assessment and treatment of HPV disease. The cumulative proportions of any genital HPV infection at 1, 3, 5, 10 and 20 years were 4.8%, 14.9%, 28.1%, 36.7% and 40.9%, respectively. Demographic, disease-related factors, chronic GvHD (cGvHD) and its treatment were analyzed for their association with persistent, multifocal or severe genital HPV disease. Pre-transplant HPV disease was strongly associated with any posttransplant HPV (odds ratio (OR)=6.5, 95% confidence interval (CI)=1.65-25.85, P=0.008). Having either extensive or genital cGvHD was associated with increased risk of any HPV disease (OR=5.7, 95% CI=1.90-17.16, P=0.002) and a higher risk for severe genital dysplasia (CIN II-III/VIN II-III; OR=13.1, 95% CI=1.59-108.26, P=0.017), but no one developed HPV-related genital cancer. Persistent, multifocal or severe HPV disease occurred more frequently than in healthy populations. Women with extensive cGvHD, genital cGvHD or pre-transplant HPV are at greatest risk for post-transplant HPV disease. Early initiation of annual screening, comprehensive genital tract assessment and active management are cornerstones of their gynecology care.
Subject(s)
Papillomaviridae/pathogenicity , Papillomavirus Infections/etiology , Stem Cell Transplantation/adverse effects , Adolescent , Adult , Female , Humans , Longitudinal Studies , Mass Screening , Middle Aged , Papillomavirus Infections/pathology , Risk Factors , Young AdultSubject(s)
Angiopoietin-2/blood , Biomarkers, Tumor/blood , Hepatic Veno-Occlusive Disease/blood , Hodgkin Disease , Interleukin-1 Receptor-Like 1 Protein/blood , Leukemia, Myeloid, Acute , Neoplasm Proteins/blood , Stem Cell Transplantation , Adult , Allografts , Female , Hepatic Veno-Occlusive Disease/etiology , Hodgkin Disease/blood , Hodgkin Disease/therapy , Humans , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/therapy , MaleSubject(s)
Biomarkers/blood , Graft vs Host Disease/blood , Graft vs Host Disease/diagnosis , Adolescent , Adult , Aged , Child , Enzyme-Linked Immunosorbent Assay , Female , Hematologic Neoplasms/therapy , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Leukemia, Myeloid, Acute/therapy , Lymphoma, Non-Hodgkin/therapy , Male , Microfluidic Analytical Techniques , Middle Aged , Myelodysplastic Syndromes/therapy , Reproducibility of Results , Retrospective Studies , Young AdultSubject(s)
Encephalitis/complications , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Stem Cell Transplantation , Toxoplasmosis/complications , Biopsy , Brain/diagnostic imaging , Brain/pathology , Encephalitis/immunology , Female , Humans , Immune System , Inflammation , Interleukin-2/therapeutic use , Magnetic Resonance Imaging , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/complications , Toxoplasmosis/immunology , Transplantation, Homologous , Treatment Outcome , Young AdultABSTRACT
AML is a diagnosis encompassing a diverse group of myeloid malignancies. Heterogeneous genetic etiology, together with the potential for oligoclonality within the individual patient, have made the identification of a single high-sensitivity marker of disease burden challenging. We developed a multiple gene measurable residual disease (MG-MRD) RQ-PCR array for the high-sensitivity detection of AML, retrospectively tested on 74 patients who underwent allo-SCT at the NHLBI in the period 1994-2012. MG-MRD testing on peripheral blood samples prior to transplantation demonstrated excellent concordance with traditional BM-based evaluation and improved risk stratification for post-transplant relapse and OS outcomes. Pre-SCT assessment by MG-MRD predicted all clinical relapses occurring in the first 100 days after allo-SCT compared with 57% sensitivity using WT1 RQ-PCR alone. Nine patients who were negative for WT1 prior to transplantation were correctly reclassified into a high-risk MG-MRD-positive group, associated with 100% post-transplant mortality. This study provides proof of principle that a multiple gene approach may be superior to the use of WT1 expression alone for AML residual disease detection.
Subject(s)
Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/therapy , Polymerase Chain Reaction/methods , Stem Cell Transplantation , Adolescent , Adult , Allografts , Child , Child, Preschool , Female , Humans , Infant , Male , Neoplasm, Residual/blood , Sensitivity and SpecificityABSTRACT
Lung nodules are common diagnostic challenges in hematopoietic stem cell transplantation and solid organ transplantation. Pseudomonas aeruginosa is a known cause of lung abscess in these patients, but its ability to persist for months in a quiescent lung nodule and later cause recurrent infection is not well known or documented. A patient with a history of acute pre-B-cell lymphoblastic leukemia had enlargement and cavitation of a small right upper lobe pulmonary nodule 10 months after allogeneic hematopoietic stem cell transplantation. The nodule was the remnant of a presumed P. aeruginosa septic embolus that occurred 2.5 months after transplantation. With antibiotic treatment, the nodule had shrunk in size to <1 cm and remained stable. Transthoracic needle aspiration grew P. aeruginosa indistinguishable by molecular typing from isolates obtained 7.5 months earlier from blood and bronchoalveolar lavage fluid. Sub-centimeter pulmonary nodules attributable to previously treated P. aeruginosa may harbor viable organisms and lead to recrudescent infection.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Lung Abscess/microbiology , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , Anti-Bacterial Agents/administration & dosage , Humans , Male , Middle Aged , Pseudomonas Infections/drug therapy , Recurrence , Time FactorsSubject(s)
Contrast Media , Coronary Artery Disease/diagnostic imaging , Stem Cell Transplantation , Tomography, X-Ray Computed , Adult , Aged , Calcium/blood , Female , Follow-Up Studies , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Male , Middle Aged , Stem Cell Transplantation/adverse effects , Survivors , Time Factors , Transplantation, Homologous , Treatment OutcomeABSTRACT
Chronic GVHD (cGVHD) is a major complication of allogeneic hematopoietic SCT. Post transplant thrombocytopenia in patients with cGVHD has been associated with poor outcome and its etiology is unclear. We investigated whether thrombopoiesis, assessed via measurement of the absolute immature platelet number (AIPN) in the blood, is impaired in cGVHD, and whether the level of thrombopoiesis correlates with the severity and activity of cGVHD as assessed via the National Institutes of Health (NIH) organ scoring system. We used a cohort of 110 well-characterized cGVHD patients, including 83 (75%) with severe cGVHD per NIH global score. Higher AIPN was associated with active therapeutic intent (P=0.026), lower Karnofsky score (P=0.0013), worse joint/fascia cGVHD (P=0.0005) and worse skin cGVHD (P=0.0044). AIPN correlated with platelet counts and was not correlated with ANC, WBC, C-reactive protein (CRP), absolute lymphocyte count (ALC), albumin, total and average NIH scores, or number of prior systemic therapies. AIPN values for cGVHD patients substantially overlapped those of the normal population. Higher AIPN, as marker of active thrombopoiesisis, was associated with worse severity and activity of cGVHD, especially skin and joints/fascia manifestations. Among patients with stable moderate or severe cGVHD, there was no evidence of hypoproduction of platelets. Future studies should further investigate the role of thrombopoiesis in cGVHD.
Subject(s)
Graft vs Host Disease/blood , Thrombocytopenia/blood , Thrombopoiesis/physiology , Adolescent , Adult , Aged , Child , Child, Preschool , Chronic Disease , Female , Graft vs Host Disease/drug therapy , Graft vs Host Disease/etiology , Humans , Male , Middle Aged , Platelet Count , Young AdultABSTRACT
Preemptive therapy at CMV reactivation has diminished post-transplant CMV mortality. Furthermore, recent studies suggest a favorable 'virus-versus-leukemia' effect from reactivating CMV, reducing relapse of AML after SCT. We studied the relationship of CMV reactivation with leukemic relapse in 110 patients with CML receiving HLA-identical sibling SCT between 1993 and 2008. Of these, 79 (72%) were in chronic phase, 5 in second chronic phase, 17 in accelerated phase and 9 in blast phase. A total of 97 patients (88%) received a myeloablative conditioning regimen, 97 received 4-log ex vivo T cell-depleted grafts and 13 received T-replete grafts. CMV reactivation before day 100 was observed in 72 patients (65.5%). At a median follow-up of 6.2 years, CMV reactivation < day 100 as a time-dependent covariate was an independent factor associated with decreased relapse. We conclude that CMV reactivation may contribute to a beneficial GVL effect in CML transplant recipients.
Subject(s)
Cytomegalovirus Infections/virology , Cytomegalovirus/physiology , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/virology , Adolescent , Adult , Aged , Female , Humans , Incidence , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Male , Middle Aged , Recurrence , Transplantation Conditioning/methods , Transplantation, Homologous , Virus Activation , Young AdultABSTRACT
Adoptive immunotherapy with ex vivo expanded T cells is a promising approach to prevent or treat leukemia. Myeloid leukemias express tumor-associated antigens (TAA) that induce antigen-specific cytotoxic T lymphocyte (CTL) responses in healthy individuals. We explored the feasibility of generating TAA-specific CTLs from stem cell donors of patients with myeloid leukemia to enhance the graft-versus-leukemia effect after stem cell transplantation. CTL lines were manufactured from peripheral blood of 10 healthy donors by stimulation with 15mer peptide libraries of five TAA (proteinase 3 (Pr3), preferentially expressed antigen in melanoma, Wilms tumor gene 1 (WT1), human neutrophil elastase (NE) and melanoma-associated antigen A3) known to be expressed in myeloid leukemias. All CTL lines responded to the mix of five TAA and were multi-specific as assessed by interferon-γ enzyme-linked immunospot. Although donors showed individual patterns of antigen recognition, all responded comparably to the TAAmix. Immunogenic peptides of WT1, Pr3 or NE could be identified by epitope mapping in all donor CTL lines. In vitro experiments showed recognition of partially human leukocyte antigen (HLA)-matched myeloid leukemia blasts. These findings support the development of a single clinical grade multi-tumor antigen-specific T-cell product from the stem cell source, capable of broad reactivity against myeloid malignancies for use in donor-recipient pairs without limitation to a certain HLA-type.
Subject(s)
Graft vs Leukemia Effect/immunology , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myeloid/therapy , Membrane Glycoproteins/immunology , T-Lymphocytes, Cytotoxic/cytology , T-Lymphocytes, Cytotoxic/immunology , Antigens, Neoplasm/immunology , Cell Line , Dendritic Cells/cytology , Dendritic Cells/immunology , Epitope Mapping , Histocompatibility Testing , Humans , Immunophenotyping , Leukemia, Myeloid/immunology , Leukocyte Elastase/immunology , Myeloblastin/immunology , Peptide Fragments/immunology , Recurrence , Tissue Donors , Transplantation, Homologous , WT1 Proteins/immunologyABSTRACT
BMI-1 and EZH2 are polycomb group (PcG) proteins that maintain self-renewal of stem cells, and are overexpressed in leukemia. To investigate the potential of PcG proteins as leukemia-associated antigens, and as targets for graft-versus-leukemia (GVL) effects, we studied cells obtained from 86 patients with chronic myeloid leukemia (CML) and 25 human leukocyte antigen (HLA)-A*0201(+) sibling donors collected before allogeneic stem cell transplantation (SCT). Although BMI-1 overexpression in CD34(+) cells of CML patients treated with pharmacotherapy is associated with poor prognosis, we found, conversely, that in CML patients treated with SCT, a higher expression of BMI-1, and correspondingly a lower expression of its target for repression, CDKN2A, is associated with improved leukemia-free survival. Cytotoxic T-lymphocyte (CTL) responses to the BMI-1 peptide were detected in 5 of 25 (20%) donors, and in 8 of 19 (42%) HLA-A*0201(+) CML patients. BMI-1 generated more total and high-avidity immune responses, and was more immunogenic than EZH2. PcG-specific CTLs had a memory phenotype, were readily expanded in short-term cultures and were detected after SCT in recipients of PcG-specific CTL-positive donors. A higher BMI-1 expression in CML CD34(+) progenitors was associated with native BMI-1 immune responses. These immune responses to PcG proteins may target leukemia stem cells and have relevance for disease control by GVL.
Subject(s)
Graft vs Host Disease/prevention & control , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Nuclear Proteins/immunology , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/immunology , Proto-Oncogene Proteins/metabolism , Repressor Proteins/immunology , Repressor Proteins/metabolism , Stem Cell Transplantation , T-Lymphocytes, Cytotoxic/immunology , Antigens, CD34/metabolism , Cohort Studies , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Enhancer of Zeste Homolog 2 Protein , Enzyme-Linked Immunosorbent Assay , HLA-A Antigens , HLA-A2 Antigen , Humans , Immunophenotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Nuclear Proteins/genetics , Peptide Fragments/immunology , Peptide Fragments/metabolism , Polycomb Repressive Complex 1 , Polycomb Repressive Complex 2 , Proto-Oncogene Proteins/genetics , RNA, Messenger/genetics , Repressor Proteins/genetics , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Transcription Factors/genetics , Transcription Factors/metabolism , Transplantation, Homologous , Treatment OutcomeABSTRACT
While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML), the disease has a high probability of relapse. Strategies to prevent relapse involve consolidation chemotherapy, stem cell transplantation and immunotherapy. Evidence for immunosurveillance of AML and susceptibility of leukaemia cells to both T cell and natural killer (NK) cell attack and justifies the application of immune strategies to control residual AML persisting after remission induction. Immune therapy for AML includes allogeneic stem cell transplantation, adoptive transfer of allogeneic or autologous T cells or NK cells, vaccination with leukaemia cells, dendritic cells, cell lysates, peptides and DNA vaccines and treatment with cytokines, antibodies and immunomodulatory agents. Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a view to achieving leukaemia cure.
Subject(s)
Immunotherapy/methods , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/therapy , Animals , Humans , Immunotherapy/trendsABSTRACT
Laboratory evidence and clinical evidence suggest that some patients with myelodysplastic syndrome (MDS) have immunologically mediated disease. This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients.
Subject(s)
Immunosuppression Therapy , Immunosuppressive Agents/therapeutic use , Myelodysplastic Syndromes/drug therapy , Adult , Aged , Aged, 80 and over , Antilymphocyte Serum/therapeutic use , Apoptosis , Biomedical Research , Bone Marrow/pathology , Clinical Medicine , Clinical Trials as Topic/statistics & numerical data , Cyclosporine/therapeutic use , Cytokines/metabolism , Female , Humans , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/pathology , T-Lymphocytes/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/physiologyABSTRACT
To determine the effects of TBI dose, fractionation and lung shielding on hematopoietic stem cell homing to the BM, BM cells were extracted from tibiae and femurs of B6-green fluorescent protein (GFP) mice and transplanted into B6 mice. Recipient mice had either: (i) no radiation, (ii) single-dose TBI at 13.6 Gy, (iii) single-dose TBI at 13.6 Gy with reduced lung exposure to 0.4 Gy by shielding, (iv) split-dose TBI at 12 Gy to twice per day over 4 days or (v) split-dose TBI at 12 Gy to twice per day over 4 days with reduced lung exposure to 0.36 Gy by shielding. The last radiation exposure preceded tail vein injection by 4-6 h. Mice were killed after 18 h. The homing of GFP-positive, lineage-negative cells was not significantly improved in any irradiated group compared with control. The homing of GFP-positive, lineage-negative, Kit-positive cells was significantly worse in all irradiated groups. TBI does not improve the homing of lineage-negative donor BM cells to the recipient marrow. The homing of lineage-negative, Kit-positive donor BM cells was significantly worse following TBI, with or without lung dose reduction.
Subject(s)
Bone Marrow/physiology , Cell Movement/physiology , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/physiology , Lung/radiation effects , Whole-Body Irradiation , Animals , Cell Movement/radiation effects , Dose-Response Relationship, Radiation , Male , Mice , Mice, Inbred C57BLABSTRACT
A total of 501 dairy cows were allocated sequentially to be treated immediately after parturition with either 25 iu oxytocin or 35 mg carbetocin, or to be left untreated. Any abnormal parturition, including assisted calving, the birth of twins or dead calves, retained fetal membranes or hypocalcaemia, was recorded, and the cows were examined between 28 and 42 days after calving for endometritis. Pregnancy was diagnosed from 30 days after insemination. The incidence of endometritis was similar (14 per cent, 16 per cent and 19 per cent) and the median intervals from calving to pregnancy were similar (118, 121 and 119 days) for the cows treated with oxytocin, carbetocin or receiving no treatment, respectively. The incidence of endometritis and the median intervals from calving to pregnancy were also similar between the groups for the cows that had an abnormal parturition.
Subject(s)
Cattle/physiology , Fertility/drug effects , Oxytocics/pharmacology , Oxytocin/analogs & derivatives , Oxytocin/pharmacology , Parturition/drug effects , Animals , Cattle Diseases/epidemiology , Endometriosis/epidemiology , Endometriosis/veterinary , Female , Fertility/physiology , Incidence , Labor, Induced/methods , Labor, Induced/veterinary , Parturition/physiology , Pregnancy , Random Allocation , Time FactorsABSTRACT
We studied thyroid function in 81 long-term survivors of allogeneic stem cell transplantation (allo-SCT), with a median follow-up of 84 months (range, 45 to 166 months). Median age at transplantation was 35 years (range, 6 to 66). Seventy-two of the patients received a total body irradiation (TBI)-containing conditioning regimen (n = 23, 12 Gy; n = 49, 13 Gy). Twenty-one of the patients (25.9%) had subclinical hypothyroidism, and 9 (11.1%) developed overt hypothyroidism at a median of 28 months (range, 3 to 78 months) after allo-SCT. Multivariate logistic regression analysis demonstrated that prolonged immunosuppressive therapy (IST) was significantly associated with subclinical hypothyroidism (odds ratio [OR] = 3.8) and overt hypothyroidism (OR = 2.6). Antithyroglobulin and thyroid peroxidase antibody were detected in 12 of 60 patients tested (20%). No correlation was found between the occurrence of thyroid antibodies and hypothyroidism (P = .13) or chronic graft-versus-host disease (cGVHD) (P = .55). In conclusion, thyroid dysfunction is relatively common after allo-SCT and is more likely to occur in patients receiving prolonged IST for cGVHD; however, thyroid dysfunction does not appear to be related to an antibody-mediated autoimmune process.
Subject(s)
Graft vs Host Disease/physiopathology , Hematopoietic Stem Cell Transplantation , Hypothyroidism/etiology , Thyroid Gland/physiopathology , Adolescent , Adult , Aged , Autoantibodies/biosynthesis , Child , Female , Graft vs Host Disease/drug therapy , Graft vs Host Disease/immunology , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/therapy , Humans , Hypothyroidism/immunology , Male , Middle Aged , Survivors , Thyroid Gland/immunology , Thyroid Gland/metabolism , Transplantation Conditioning , Whole-Body Irradiation , Young AdultABSTRACT
Malignant diseases induce immune responses against them which have variable success in controlling progression of disease. A variety of congenital and acquired disorders provide evidence in support of T cell or NK cell immune surveillance mechanisms in human hematological malignancies. Furthermore, clinical experience with stem cell transplantation underlines the potential for both T and NK cell-mediated antileukemia effects. Animal models of tumor surveillance and viral-driven lymphoproliferative diseases in man emphasize the dynamic nature of the equilibrium between tumors and the immune system, which can lead to tumor escape in individuals with normal immune function. In hematological malignancies the implication of a dynamic immune surveillance model is that chemotherapy may disrupt potentially competent immune surveillance mechanisms leading to disease recurrence following successful tumor bulk reduction by chemotherapy. This possibility deserves further investigation with a view to developing strategies to boost immune function following chemotherapy so as to combine the beneficial effect of chemotherapy with an immune response capable of sustaining remissions.
Subject(s)
Antineoplastic Agents/adverse effects , Immunologic Surveillance/drug effects , Animals , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/immunology , Humans , Tumor Escape/drug effects , Tumor Escape/immunologyABSTRACT
The cure of chronic myeloid leukemia (CML) patients following allogeneic stem cell transplantation (SCT) is attributed to graft-versus-leukemia (GVL) effects targeting alloantigens and/or leukemia-associated antigens (LAA) on leukemia cells. To assess the potential of LAA-peptide vaccines in eliminating leukemia in CML patients, we measured WT1, PR3, ELA2 and PRAME expression in CD34+ progenitor subpopulations in CML patients and compared them with minor histocompatibility antigens (mHAgs) HA1 and SMCY. All CD34+ subpopulations expressed similar levels of mHAgs irrespective of disease phase, suggesting that in the SCT setting, mHAgs are the best target for GVL. Furthermore, WT1 was consistently overexpressed in advanced phase (AdP) CML in all CD34+ subpopulations, and mature progenitors of chronic phase (CP) CML compared to healthy individuals. PRAME overexpression was limited to more mature AdP-CML progenitors only. Conversely, only CP-CML progenitors had PR3 overexpression, suggesting that PR1-peptide vaccines are only appropriate in CP-CML. Surface expression of WT1 protein in the most primitive hematopoietic stem cells in AdP-CML suggest that they could be targets for WT1 peptide-based vaccines, which in combination with PRAME, could additionally improve targeting differentiated progeny, and benefit patients responding suboptimally to tyrosine kinase inhibitors, or enhance GVL effects in SCT patients.